EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSCGOG00000014984
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSCGOG00000012626
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSCGOG00000022776
Gene Symbol: MLNR
3 Cross references
172 Possible Orthologues:

Muscarinic Acetylcholine Receptor M2-Like

Ensembl ID : ENSCGOG00000012120
Gene Symbol: LOC115028109
3 Cross references
196 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSCGOG00000019203
Gene Symbol: LOC115027436
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSCGOG00000004677
Gene Symbol: NPR1
3 Cross references
193 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSCGOG00000008686
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSCGOG00000004611
Gene Symbol: LOC115016711
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSCGOG00000016477
Gene Symbol: LOC115013071
3 Cross references
200 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSCGOG00000010613
Gene Symbol: LOC115011663
3 Cross references
194 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-2-Like

Ensembl ID : ENSCGOG00000022504
Gene Symbol: LOC115010808
3 Cross references
195 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSCGOG00000011361
Gene Symbol: LOC115006454
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).